There are no items in your cart.
Home > Archive by category 'PPM Blog'

PPM Blog

Bankia plummets on deposit drain concerns

– Bankia shares fall as much as 29%; end down 14% — Report on deposit withdrawals adds to worries — Bankia, government denies the bank is losing deposits MADRID — The Spanish government moved Thursday to quell fears of massive [...]

Audio: Radio update: Wal-Mart tops earnings forecasts

The latest money news from Ann Cates, including a report that losses at JPMorgan Chase may be steeper than first thought. Read More

Spain’s Bankia: Depositors have nothing to fear

MADRID (MarketWatch) — Spanish lender Bankia SA said depositors have “nothing to fear,” in a statement issued Thursday in reponse to a report in El Mundo that customers have withdrawn 1 billion euros ($1.3 billion). Shares tumbled 11% on Thursday, [...]

Wal-Mart probed by SEC, DOJ, Mexican agencies

NEW YORK (MarketWatch) — Wal-Mart Stores Inc. , undergoing an internal investigation into whether it allegedly violated the U.S. Foreign Corrupt Practices Act in its Mexican market and whether prior allegations were mishandled by the company, said in a regulatory [...]

CFTC may change application of speculative limits

WASHINGTON (MarketWatch) — The Commodity Futures Trading Commission is considering changing how it tallies positions under new limits on speculation in commodity markets, according to people familiar with the matter. Read More

Big energy companies fret over fracking: study

Energy companies reportedly have more concerns over the risks associated with key shale-gas technology. Read More

Are you ready for water inflation?

We haven’t learned any lessons from the ethanol debacle. Read More

Cody Willard on Apple suppliers, oil, Greece and more

All right guys, ask me anything. Read More

Financial Stocks: J.P. Morgan weighs on financial stocks

J.P. Morgan Chase & Co. falls more than 4% after a report of further derivatives losses. Sector is further pressured by grim economic data. Read More

Osiris stem-cell therapy wins Canadian approval

BOSTON (MarketWatch) — Shares of Osiris Therapeutics jumped 14% to $5.60 in after-hours trading Thursday on news that Canadian regulators have approved its product Prochymal for the treatment of acute graft-vs-host disease, or GVHD, in children. GVHD is a life-threatening [...]